In the late phase (last 6 months, from day 211 to day 395), GLP-1 RA Users maintained a reduced risk of all-cause death (HR 0.646, 95% CI 0.627–0.666) and a higher risk of pancreatic cancer (HR 1.109, 95% CI 1.006–1.223). Here, GLP1R is linked to pancreatic neoplasm.